Boryung Commences Construction of New Penicillin Manufacturing Facility

Boryung (CEO and Chairman, Jay Kim) announced that it has held a groundbreaking ceremony for the expansion of its penicillin production facilities at the Boryung Ansan Campus in Ansan, Gyeonggi Province. 

The ceremony was attended by key government and industry representatives, including National Assembly Member Hae Cheol Park (Ansan-si Byeong District); Myung Ho Kim, Director of the Gyeongin Regional Office of the Ministry of Food and Drug Safety; Woon Hak Kim, Head of Industrial Support Division of Ansan City; Hang Shin Lee, Executive Director of the Korea Health Industry Development Institute; Yeon Hong Roh, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association; and Hyung Sun Ryu, Chairman of the Korea Pharmaceutical Traders Association. 

The expanded Ansan Campus will introduce systems and equipment aligned with global manufacturing and quality standards. Digital transformation initiatives―including automated packaging systems and process-innovation technologies―will be incorporated to reduce operational burden, minimize human error, and enhance both productivity and product consistency. 

Oral penicillin antibiotics were designated as national essential treatments by the Ministry of Food and Drug Safety in 2023, following continued supply instability during and after the COVID-19 pandemic. Boryung has historically served as Korea’s largest manufacturing base for these products, accounting for more than 60% of domestic contract-manufacturing volume. Through this expansion, the company aims to fortify its capacity to ensure uninterrupted supply, even during public-health emergencies. 

Yeon Hong Roh, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, commented, “The establishment of this expanded production base marks a significant milestone in strengthening the nation’s antibiotic supply chain and advancing domestic self-sufficiency. We look forward to this initiative serving as a strong foundation for the future of the industry and public health.” 

Hyung Sun Ryu, Chairman of the Korea Pharmaceutical Traders Association, stated, “This investment is not simply an industrial advancement but a commitment to safeguarding lives by protecting national pharmaceutical sovereignty. We will continue to extend full support to reinforce the essential treatment supply chain and enhance export competitiveness.” 

Jay Kim, CEO and Chairman of Boryung, remarked, “This expansion represents a meaningful step forward in elevating the production quality and supply capacity of penicillin antibiotics, a national essential treatment. Boryung will continue to strengthen the stability of the essential treatment supply chain and fulfill its responsibility as a company dedicated to protecting public health.”